Have you been diagnosed with B-cell post-transplant lymphoproliferative disorder (PTLD) after an organ transplant? Have you not yet received any type of treatment for this condition? Then you may be eligible for a study to look at the safety and effectiveness of tafasitamab and rituximab combination treatment for PTLD.

The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must have already received or were not able to tolerate the standard of care, except for specific groups who have not had cancer treatment.

Do you have a new diagnosis of Acute Myeloid Leukemia and are looking for another treatment option? In this study, we are looking to see if the study drug (Tagraxofusp) can help control Leukemia or achieve remission.

The purpose of this study is to find out if we can improve the chance of your leukemia going away (remission) and lower the chance of your leukemia coming back (relapsing) by combining two drugs for acute lymphoblastic leukemia. In this study you will be given the first study drug (Inotuzumab Ozogamicin) for up to 7 weeks and then a second leukemia drug (Blinatumomab) for up to 31 weeks.

Have you been diagnosed with unfavorable risk prostate cancer? Are you looking for treatment options? If so, you may be able to participate in a clinical trial examining different treatment options for prostate cancer.

Researchers at the University of North Carolina at Chapel Hill are studying innovative ways to promote healthy eating, physical activity, and weight loss in young adults using a smartphone app, digital health tools, and daily messaging. We are seeking volunteers to enroll in a 6-month research study that tests a smartphone-delivered weight loss program designed specifically for young adults.

Have you been recently diagnosed with Acute Lymphoblastic Leukemia? If so, you may be able to take part in a research study to help us learn more about the effects of using Tyrosine Kinase Inhibitor (TKI), steroids and blinatumomab versus treatment with steroids, Tyrosine Kinase Inhibitor (TKI) and chemotherapy.

Do you have small cell lung cancer, large cell neuroendocrine cancer, neuroendocrine prostate cancer, or gastroenteropancreatic neuroendocrine carcinomas? Have you been treated with existing standard of care treatments that did not work? You may be able to take part in a research study to test a new drug for these types of cancer.

This study is being done to answer the following question: Can we lessen the pain you have and improve the way you live with cancer that has spread to the bone by adding a new drug to the usual drug given? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your advanced renal cell cancer. The usual approach is defined as care most people get for advanced renal cell cancer.

Do you have locally advanced, inoperable, node-positive non-small cell lung cancer (NSCLC), stage II or III? If so, you may be able to take part in a study to learn more about the effectiveness of adding stereotactic body radiation therapy (SBRT) to the standard treatment of radiation and chemotherapy.